18 Jul Cojourney
Lijun Wang, Ph.D., Founder and CEO
Oct. 7 | 2:45pm | FLW Ballroom G
Lower Gwynedd, PA
(Private)
Key Considerations of Plasmid Manufacturing for Viral Vector Production
In the ever-evolving world of cell and gene therapy, the demand for high-quality, scalable, and regulatory-compliant plasmid DNA is at an all-time high. Traditional plasmid manufacturing workflows rely heavily on column chromatography, a time-consuming and costly purification method that involves multiple steps, significant infrastructure, and complex scale-up challenges.
CoJourney’s Zero Chrom® Plasmid Platform eliminates the need for column chromatography entirely—ushering in a new era of simplified, high-throughput, and scalable plasmid production. This innovation not only streamlines manufacturing but also lowers regulatory risk and dramatically reduces production timelines. Key benefits of the platform include:
Faster Purification: No column chromatography means shorter production cycles and lower costs.Low Regulatory Risk: Use of single-use systems reduces the potential for cross-contamination—critical in clinical-grade manufacturing.Superior Quality: Produces plasmid DNA with >95% supercoiled structure, ideal for therapeutic applications.FDA & NMPA Approved: Zero Chrom® plasmids have been used in IND-approved programs across major markets.Scalable Output: Supports both research-grade and GMP-grade plasmid DNA production ranging from 1L to 30L, with a proven capacity of over 300 batches per year.
Meet the Visionary:
Dr. Lijun Wang, a molecular biologist and industry veteran, will be on-site to answer questions and discuss how CoJourney’s manufacturing platforms are accelerating gene and cell therapy programs worldwide. Her presentation will highlight the technical innovations behind Zero Chrom®, including its upstream and downstream integration, data on yield consistency, and adaptability across gene therapy modalities.
